MétaCan
Menu
Back to cohort

Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide

2025· article· en· W4414869610 on OpenAlexfundno aff
Dipenkumar Modi, Yosra Aljawai, Todd E. DeFor, Caitrin Bupp, Monzr M. Al Malki, Javier Bolaños‐Meade, Mahasweta Gooptu, Antonio Jiménez, Hongtao Liu, Felix Mensah, Marco Mielcarek, Brian C. Shaffer, Bronwen E. Shaw, Stephen R. Spellman, Heather E. Stefanski, Jeffery J. Auletta, Steven M. Devine, Farhad Khimani, Ramzi Abboud

Bibliographic record

VenueBlood Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsnot available
FundersCancer MoonshotNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchU.S. NavyLegend BiotechAlexion Pharmaceuticalsbluebird bioPharmacyclicsDaiichi Sankyo EuropeTakeda OncologyAstellas Pharma USUniversity of Texas MD Anderson Cancer CenterAstraZenecaGenentechAdaptive BiotechnologiesHealth Resources and Services AdministrationNational Institutes of HealthJanssen Research and DevelopmentMorphoSysSeagenCareDxBeiGeneSwedish Orphan BiovitrumAstellas PharmaKiadis PharmaMedacJazz PharmaceuticalsOmeros CorporationKaryopharm TherapeuticsHistoGeneticsEli Lilly and CompanyU.S. Department of DefenseMoonshot Research and Development ProgramSanofiCSL BehringBristol-Myers SquibbVertex PharmaceuticalsMallinckrodt PharmaceuticalsGateway for Cancer ResearchActinium PharmaceuticalsNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationIncytePfizerAmgenAtara BiotherapeuticsNational Cancer InstituteGilead Sciences
KeywordsCyclophosphamideProportional hazards modelConfidence intervalTransplantationHematopoietic cellAcute leukemiaHematopoietic stem cell transplantationGraft-versus-host disease

Abstract

fetched live from OpenAlex

ABSTRACT: Posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is now standard for matched unrelated donor (MUD) hematopoietic cell transplantation (HCT). Previous studies comparing MUD and haploidentical donor HCT using PTCy were limited in size and follow-up. We therefore performed a registry-based analysis examining the impact of donor type on HCT with PTCy. Adult patients (n = 5873) receiving MUD (n = 1973) or haploidentical (n = 3900) HCT with PTCy for acute leukemia (74.2%) or myelodysplastic syndrome (MDS; 25.8%) reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021 were included. Primary end points were 3-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS). Cox regression and sensitivity analyses were performed through adjustment of propensity scores. Haploidentical HCT had worse OS (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.04-1.27; P = .005) and GRFS (HR, 1.19; 95% CI, 1.10-1.29; P < .001) versus MUD HCT. Donor age was the only other donor factor associated with survival. Results were confirmed in sensitivity analysis. When restricted to reduced intensity conditioning or donors <30 years, OS did not differ between groups. Haploidentical HCT was associated with higher primary graft failure (HR, 1.67; P = .002), increased grade 3/4 acute GVHD (HR, 1.28; P = .039), higher moderate/severe chronic GVHD (HR, 1.47; P < .001), and nonrelapse mortality (HR, 1.34; P < .001). Grade 2 to 4 acute GVHD and relapse risk did not differ. This large analysis showed that in adults with acute leukemia or MDS, MUD HCT was associated with improved outcomes versus haploidentical HCT with PTCy-based GVHD prophylaxis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.191
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.274
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207